#USA #Robbins Geller #San Diego #Class Action #Inc. #GRAIL

Grail, Inc. Class Action Alert

Investors holding shares of Grail, Inc. (NASDAQ: GRAL) are being urged to take action following significant financial losses. The law firm Robbins Geller Rudman & Dowd LLP has initiated a class action lawsuit on behalf of all individuals who purchased or acquired common stock during the class period, which spans from May 13, 2025, to February 19, 2026. This lawsuit is now officially titled Robbins v. Grail, Inc., and is established in the Northern District of California, under case number 26-cv-05428.

Background of Grail, Inc.

Grail, Inc. is a healthcare technology company focusing on early cancer detection through innovative testing services. One of their flagship products, Galleri, is designed for asymptomatic individuals over the age of 50. Galleri functions as a diagnostic aid aimed at identifying potential cancers early, thereby accelerating the diagnosis process for patients. The NHS-Galleri trial was particularly significant, as it sought to demonstrate a statistically significant reduction in late-stage cancers among those who utilized the Galleri test compared to those who did not.

Allegations in the Class Action

The lawsuit asserts that Grail and certain executive officers made a series of misleading statements regarding their testing capabilities and trial outcomes. Key allegations include:

• - The management created an impression that their information regarding the NHS-Galleri trial's endpoint achievements was reliable, while they allegedly concealed adverse facts that decreased the likelihood of success.
• - Grail's claims about achieving positive results were exaggerated and did not align with the actual data analysis emerging from the trial findings.
• - On February 19, 2026, the company revealed that the anticipated reduction in Stage III and IV cancers was not achieved as planned, which led to a drastic decline in their stock price by over 50%.

The Importance of Participation

For those who have suffered financial losses, the opportunity to act as a lead plaintiff in the Grail class action lawsuit is important. The Private Securities Litigation Reform Act of 1995 allows any investor who qualifies to seek this role. The lead plaintiff is typically the one with the most significant financial interest in the case and must also be representative of other class members. This role is crucial as it involves spearheading the lawsuit and can greatly influence the outcome for all involved shareholders.

Those interested in becoming a lead plaintiff can find more information here. If you have questions or need further assistance, contacting attorneys Ken Dolitsky or Michael Albert at Robbins Geller is encouraged. They can be reached at 800/851-7783 or via email at [email protected].

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is recognized globally as a leading law firm specializing in securities fraud and shareholder rights litigation. In 2025 alone, the firm secured over $916 million for investors, positioning them at the top of their field. Their historical success includes recovering $8.4 billion for clients over the past five years, underscoring their expertise and the importance of legal representation in securities class actions.

Investors are strongly urged to act promptly to protect their interests and explore their legal options regarding the ongoing developments at Grail, Inc.